Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.

CONCLUSION: These findings suggest that changes in NSAID intake during treatment do not prevent demonstration of clinically relevant effects of biologic treatment, and combined (i.e., clinical with NSAID-sparing) endpoints were frequently more discriminant than single (i.e., clinical) endpoints. ClinicalTrials.gov (NCT01298531).
PMID: 26568588 [PubMed - as supplied by publisher]

Source: J Rheumatol - November 15, 2015 Category: Rheumatology Authors: Dougados M, Wood E, Gossec L, Dubanchet A, Logeart I, van der Heijde D Tags: J Rheumatol Source Type: research